229 related articles for article (PubMed ID: 19743941)
1. Besifloxacin, a new ophthalmic fluoroquinolone for the treatment of bacterial conjunctivitis.
Bertino JS; Zhang JZ
Expert Opin Pharmacother; 2009 Oct; 10(15):2545-54. PubMed ID: 19743941
[TBL] [Abstract][Full Text] [Related]
2. Besifloxacin: a topical fluoroquinolone for the treatment of bacterial conjunctivitis.
Chang MH; Fung HB
Clin Ther; 2010 Mar; 32(3):454-71. PubMed ID: 20399984
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study in adults and children.
Silverstein BE; Allaire C; Bateman KM; Gearinger LS; Morris TW; Comstock TL
Clin Ther; 2011 Jan; 33(1):13-26. PubMed ID: 21397770
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% in children and adolescents with bacterial conjunctivitis: a post hoc, subgroup analysis of three randomized, double-masked, parallel-group, multicenter clinical trials.
Comstock TL; Paterno MR; Usner DW; Pichichero ME
Paediatr Drugs; 2010 Apr; 12(2):105-12. PubMed ID: 20218747
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis.
McDonald MB; Protzko EE; Brunner LS; Morris TW; Haas W; Paterno MR; Comstock TL; Usner DW
Ophthalmology; 2009 Sep; 116(9):1615-1623.e1. PubMed ID: 19643483
[TBL] [Abstract][Full Text] [Related]
6. Besifloxacin ophthalmic suspension, 0.6%: a novel topical fluoroquinolone for bacterial conjunctivitis.
O'Brien TP
Adv Ther; 2012 Jun; 29(6):473-90. PubMed ID: 22729919
[TBL] [Abstract][Full Text] [Related]
7. Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study.
Karpecki P; Depaolis M; Hunter JA; White EM; Rigel L; Brunner LS; Usner DW; Paterno MR; Comstock TL
Clin Ther; 2009 Mar; 31(3):514-26. PubMed ID: 19393842
[TBL] [Abstract][Full Text] [Related]
8. Besifloxacin ophthalmic suspension for bacterial conjunctivitis.
Nafziger AN; Bertino JS
Drugs Today (Barc); 2009 Aug; 45(8):577-88. PubMed ID: 19927224
[TBL] [Abstract][Full Text] [Related]
9. Besifloxacin ophthalmic suspension 0.6%.
Carter NJ; Scott LJ
Drugs; 2010; 70(1):83-97. PubMed ID: 20030427
[TBL] [Abstract][Full Text] [Related]
10. Safety and tolerability of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis: data from six clinical and phase I safety studies.
Comstock TL; Paterno MR; Decory HH; Usner DW
Clin Drug Investig; 2010; 30(10):675-85. PubMed ID: 20629472
[TBL] [Abstract][Full Text] [Related]
11. The role of besifloxacin in the treatment of bacterial conjunctivitis.
Mahvan TD; Hornecker JR; Buckley WA; Clark S
Ann Pharmacother; 2014 May; 48(5):616-25. PubMed ID: 24566460
[TBL] [Abstract][Full Text] [Related]
12. The role of topical moxifloxacin, a new antibacterial in Europe, in the treatment of bacterial conjunctivitis.
Benitez-Del-Castillo J; Verboven Y; Stroman D; Kodjikian L
Clin Drug Investig; 2011; 31(8):543-557. PubMed ID: 21604820
[TBL] [Abstract][Full Text] [Related]
13. Besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis in adults and children.
DeLeon J; Silverstein BE; Allaire C; Gearinger LS; Bateman KM; Morris TW; Comstock TL
Clin Drug Investig; 2012 May; 32(5):303-17. PubMed ID: 22420526
[TBL] [Abstract][Full Text] [Related]
14. Besifloxacin Ophthalmic Suspension 0.6% Compared with Gatifloxacin Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis in Neonates.
Sanfilippo CM; Allaire CM; DeCory HH
Drugs R D; 2017 Mar; 17(1):167-175. PubMed ID: 28078599
[TBL] [Abstract][Full Text] [Related]
15. Ocular pharmacokinetics/pharmacodynamics of besifloxacin, moxifloxacin, and gatifloxacin following topical administration to pigmented rabbits.
Proksch JW; Ward KW
J Ocul Pharmacol Ther; 2010 Oct; 26(5):449-58. PubMed ID: 20874668
[TBL] [Abstract][Full Text] [Related]
16. Microbiological etiology and susceptibility of bacterial conjunctivitis isolates from clinical trials with ophthalmic, twice-daily besifloxacin.
Haas W; Gearinger LS; Hesje CK; Sanfilippo CM; Morris TW
Adv Ther; 2012 May; 29(5):442-55. PubMed ID: 22644963
[TBL] [Abstract][Full Text] [Related]
17. Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis.
Tepedino ME; Heller WH; Usner DW; Brunner LS; Morris TW; Haas W; Paterno MR; Comstock TL
Curr Med Res Opin; 2009 May; 25(5):1159-69. PubMed ID: 19323612
[TBL] [Abstract][Full Text] [Related]
18. The safety of besifloxacin ophthalmic suspension 0.6 % used three times daily for 7 days in the treatment of bacterial conjunctivitis.
Malhotra R; Ackerman S; Gearinger LS; Morris TW; Allaire C
Drugs R D; 2013 Dec; 13(4):243-52. PubMed ID: 24142473
[TBL] [Abstract][Full Text] [Related]
19. Characterization of baseline polybacterial versus monobacterial infections in three randomized controlled bacterial conjunctivitis trials and microbial outcomes with besifloxacin ophthalmic suspension 0.6.
DeCory HH; Sanfilippo CM; Proskin HM; Blondeau JM
PLoS One; 2020; 15(8):e0237603. PubMed ID: 32841261
[TBL] [Abstract][Full Text] [Related]
20. Safety of besifloxacin ophthalmic suspension 0.6% in cataract surgery patients.
Parekh JG; Newsom TH; Nielsen S
J Cataract Refract Surg; 2012 Oct; 38(10):1864-7. PubMed ID: 22999608
[No Abstract] [Full Text] [Related]
[Next] [New Search]
